Bellen Chemistry nets hundreds of millions of yuan in Series D round

On June 30, Bellen Chemistry completed several hundred million yuan in its Series D round of financing, which was jointly led by Huagai Capital and Eastern Bell Venture Capital.

On June 30, Bellen Chemistry completed several hundred million yuan in its Series D round of financing, which was jointly led by Huagai Capital and Eastern Bell Venture Capital.

The round also saw participation from existing investors such as Zhongjin Qichen, Legend Capital, Apricot Capital, Insight Capital, among others.

Proceeds from this round of financing will continue to be used for the development of the company’s CRO/CDMO business and the construction of a one-stop service platform for chemical synthesis of small molecule drug discovery and development.

Founded in 2010, Bellen Chemistry is mainly involved in the R&D outsourcing and manufacturing outsourcing services (CRO/CDMO) of high-end pharmaceutical intermediates, and is committed to building a global leading one-stop service platform for the R&D and chemical synthesis of small molecule novel drugs.

The company has an early-stage R&D laboratory in Beijing, a process R&D center in Shanghai, a production base of nearly 100 acres in Yantai, Shandong Province, and marketing and sales centers in France, Canada, the US, the UK, and Japan.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/03/bellen-chemistry-nets-hundreds-of-millions-of-yuan-in-series-d-round/.

Leave a Reply

Please Login to Comment